Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Sibutramine (Primary)
- Indications Obesity; Overweight
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms SCOUT
- Sponsors Abbott Laboratories
- 12 May 2012 Results presented at the 19th European Congress on Obesity.
- 08 Oct 2010 Based primarily on the results of this trial, Abbott will voluntarily withdraw sibutramine from the Canadian market.
- 08 Oct 2010 Based primarily on the results of this trial, Abbott will voluntarily withdraw sibutramine from the US market at the request of the US FDA.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History